Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib MET-PET/CT Study in EGFR-mutant NSCLC with brain metastases
jRCTs031180271Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Change in brain metastasis amino acid metabolic activity on MET-PET/CT. Started May 2018; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180271.